Положительное влияние ацетил-L-карнитина на болевой синдром, регенерацию нервов и вибрационное чувство у пациентов с хронической диабетической нейропатией. Анализ результатов двух рандомизированных плацебоконтролируемых исследований

Обложка

Цитировать

Полный текст

Об авторах

Anders A.F. Sima

Departments of Pathology and Neurology, Wayne State University, Detroit, MI

Автор, ответственный за переписку.
Email: fake@neicon.ru
Россия

Menotti Calvani

Sigma-Tau spA, Pomezia, Rome, Italy

Email: fake@neicon.ru
Россия

Munish Mehra

Medifacts International, Rockville, MD

Email: fake@neicon.ru
Россия

Antonino Amato

Sigma-Tau Research, Gaithersburg, MD

Email: fake@neicon.ru
Россия

Список литературы

  1. Sugimoto K., Murakawa Y., Sima A.A.F. Diabetic neuropathy: a continuing enigma. Diabetes Metab Res Rev2000;16:408–33.
  2. Sima A.A.F. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003;60:2445–64.
  3. Dyck P.J., Thomas P.K. Diabetic polyneuropathy. In: Diabetic Neuropathy. Philadelphia: W.B. Saunders, 1999; p. 239–406.
  4. Sima A.A.F. Diabetic neuropathy: pathogenetic background, current and future therapies. Expert Rev Neurotherapeutics 2001;1:225–38.
  5. Fagius J., Brattberg A., Jameson S., Berne C. Limited benefits of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-wk controlled trial. Diabetologia 1985;28:323–9.
  6. Sima A.A.F., Bril V., Nathaniel V. et al. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor. N Engl J Med 1988;319: 548–55.
  7. Boulton A.J.M., Levin S., Comstock J.A. A multicenter trial of the aldose reductase inhibitor tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431–7.
  8. Macleod A.F., Boulton A.J.M., Owens D.R. et al. A multicenter trial of the aldose reductase inhibitor in patients with symptomatic diabetic peripheral neuropathy. Diabetes Metab 1992;8: 14 –20.
  9. Pfeifer M.A., Schumer M.P., Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial design. Diabetes 1997;46:582–9.
  10. Ziegler D., Hanefeld M., Ruhnau K.-J. et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid. Diabetes Care 1999;22:1296–301.
  11. Scarpini E., Doneda P., Pizzul S. et al. L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects. J Peripher Nerv Syst 1996;1:157–63.
  12. Ido Y., McHowat J., Chang K.C. et al. Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-Lcarnitine. Diabetes 1994;43:1469–77.
  13. Sima A.A., Ristic H., Merry A. et al. The primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996;97:1900–7.
  14. Williamson J.R., Arrigoni-Martelli E. The role of glucose-induced metabolic hypoxia and imbalances in carnitine metabolism in mediating diabetes-induced vascular dysfunction. Int J Clin Pharmacol Res 1992;12:247–52.
  15. Stevens M.J., Lattimer S.A., Feldman E.L. t al. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na-/K--ATPase activity and motor conduction velocity in the streptocin diabetic rat. Metabolism 1996;45:865–72.
  16. Lowitt S., Malone J.I., Salem A.F. et al. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 1995;44:677–80.
  17. Scarpini E., Sacilotto G., Baron P. et al. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIVpatients. J Peripher Nerv Syst 1997;2:250 –2.
  18. Onofrj M., Fulgente T., Melchionda D. et al. L-acetyl-carnitine as a new therapeutic approach for peripheral neuropathies with pain. Int J Clin Pharmacol Res 15:9–15.
  19. Quatraro A., Roca P., Donzella C. et al. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 1995;38:123.
  20. Report and recommendations of the San Antonio Conference on diabetic neuropathy. Diabetes 1988;37:1000–4.
  21. Laudadio C., Sima A.A.F. Design of controlled clinical trials for diabetic polyneuropathy. Semin Neurol 1996;16:187–91.
  22. Sima A.A.F., Blaivas M. Peripheral neuropathies. In Neuropathology: The Diagnostic Approach. Garcia J., McKeevar P., Sima A.A.F., Eds. Philadelphia: Mosby, 1997, p. 765–809.
  23. O’Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079–87.
  24. Arezzo J.C., Schaumburg H.H., Laudadio C. The Vibratron: a simple device for quantitative evaluation of tactile/vibratory sense (Abstract). Neurology 1985;35 (Suppl. 1):169.
  25. Greene D.A., Arezzo J.C., Brown M.D., the Zenarestat Study Group: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999;53:580–91.
  26. Bohning D. Computer-Assisted Analysis of Mixtures and Applications. New York: Chapman and Hall/CRC, 1999.
  27. Burchiel K.J., Russel L.C., Lee R.P., Sima A.A.F. Spontaneous activity of primary afferent neurons in diabetic BB-Wistar rats: a possible mechanism of chronic pain. Diabetes 1985;34:1210–3.
  28. Dyck P.K., Lambert E.H., O’Brien P.C. Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 1976;26:466–71.
  29. Kapur D. Neuropathic pain and diabetes. Diabetes Metab Res Rev 2003;19:9–15.
  30. Singleton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001;24:1448–53.
  31. Murakawa Y., Zhang W., Pierson C.R. et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab Res Rev 2002;18:473–83.
  32. Kamiya H., Zhang W., Sima A.A.F. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol. In press.
  33. Chiechio S., Caricasole A., Barletta E. et al. L-acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Molecul Pharm 2002;61:1– 8.
  34. Tomlinson D.R., Fernyhough P., Diemal L.T. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factor. Diabetes 1997;46 (Suppl 2):543–9.
  35. DiGiulio A.M., Gorio A., Bertelli A. et al. Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals. Int J Clin Pharmacol Res 1992;12:243–6.
  36. Woolf C.J., Mannison R.J. Neuropathic pain: etiology, symptoms, mechanisms and management. Lancet 1999;353:1959–64.
  37. Woolf C.J., Shortland P., Coggeshall R.E. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992;355:75–8.
  38. Sima A.A.F., Kamiya H. Insulin, C-peptide, and diabetic neuropathy. Sci Med 2004;10:308–19.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© A.F. Sima A., Calvani M., Mehra M., Amato A., 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.